All articles by Adam Zamecnik

Adam Zamecnik

@a_zamecnik

Adam Zamecnik is a healthcare reporter for Pharmaceutical Technology. He has covered diverse topics such as continuous drug manufacturing, genomic research and sexual health. He is particularly interested in new technologies, health inequality, and cell and gene therapy research.

CTO Europe 2023: A snapshot of challenges and opportunities in oncology

Global developments and old challenges clash with the arrival of new technologies for drug development in oncology, creating both opportunities…
CTO Europe 2023: Fostering diverse oncology trials remains a challenge

Lacking diversity in clinical trials remains a challenge as 73% of global study participants are white, based on data presented…
CTO Europe 2023: Reflections on drug development through the phases

Precision medicine oncology trial designs improve the likelihood of a drug’s approval by 38%, based on a presentation held by…
CTO Europe 2023: Cancer clinical trials shift as sector goes digital

Building on the increased adoption of digital trial capabilities due to the Covid-19 pandemic, the future of clinical trials will…
UK rejoins EU’s Horizon Europe science programme

The UK has re-joined the EU’s Horizon Europe science research programme after the country’s post-Brexit absence and long-stalled talks. British…

Halia plans two trials testing its anti-inflammatory lead candidate

Halia Therapeutics is planning to start two Phase II trials evaluating its lead drug HT-6184 before the end of the…
Regulatory roundup: Ascendis’ shot at further study in achondroplasia jumps

Need to know: GlobalData’s Investigative News team reviews data generated by an in-house model that combines machine learning and its…
ASH hot topic: site selection key in reducing disparity in cancer trials

Diversity, equity, and inclusion in clinical trials was a hot topic in several abstracts presented at the recent Annual Meeting…
Regulatory roundup: Xenon’s shot at further study in focal epilepsy leaps after positive Phase IIb

Need to know: GlobalData’s Investigative News team reviews data generated by an in-house model that combines machine learning and its…
Regulatory roundup: Veru’s likelihood of further study in vasomotor symptoms jumps after Phase II completion

Need to know: GlobalData’s Investigative News team reviews data generated by an in-house model that combines machine learning and its…